Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 31 | 2023 | 1268 | 4.250 |
Why?
|
Liver Cirrhosis | 12 | 2017 | 297 | 2.090 |
Why?
|
Antiviral Agents | 12 | 2019 | 510 | 1.490 |
Why?
|
Hepatitis C, Chronic | 7 | 2019 | 126 | 1.470 |
Why?
|
Hepatitis C | 7 | 2013 | 208 | 1.330 |
Why?
|
Tissue Donors | 8 | 2023 | 463 | 1.310 |
Why?
|
Immunosuppressive Agents | 12 | 2022 | 977 | 1.230 |
Why?
|
Organ Transplantation | 4 | 2023 | 265 | 1.030 |
Why?
|
Hepacivirus | 7 | 2019 | 159 | 1.020 |
Why?
|
Liver Failure | 3 | 2019 | 78 | 0.880 |
Why?
|
Hepatitis, Autoimmune | 2 | 2016 | 19 | 0.800 |
Why?
|
Viral Load | 3 | 2019 | 148 | 0.740 |
Why?
|
Liver Diseases | 5 | 2021 | 238 | 0.720 |
Why?
|
End Stage Liver Disease | 3 | 2017 | 61 | 0.690 |
Why?
|
Intestinal Polyps | 1 | 2018 | 26 | 0.660 |
Why?
|
Chemical and Drug Induced Liver Injury | 2 | 2014 | 69 | 0.660 |
Why?
|
Stomach Diseases | 1 | 2018 | 19 | 0.660 |
Why?
|
Duodenal Diseases | 1 | 2018 | 24 | 0.660 |
Why?
|
Hypertension, Portal | 1 | 2018 | 47 | 0.650 |
Why?
|
Gastric Mucosa | 1 | 2018 | 66 | 0.640 |
Why?
|
Ribavirin | 5 | 2016 | 57 | 0.630 |
Why?
|
Liver Neoplasms | 7 | 2021 | 736 | 0.620 |
Why?
|
Graft Survival | 7 | 2023 | 884 | 0.610 |
Why?
|
Rifamycins | 1 | 2016 | 5 | 0.590 |
Why?
|
Hepatorenal Syndrome | 1 | 2016 | 8 | 0.580 |
Why?
|
Heart Transplantation | 4 | 2021 | 705 | 0.570 |
Why?
|
Anti-Infective Agents | 1 | 2016 | 89 | 0.540 |
Why?
|
Humans | 68 | 2023 | 86643 | 0.530 |
Why?
|
Deficiency Diseases | 1 | 2015 | 10 | 0.530 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 1036 | 0.520 |
Why?
|
Tissue and Organ Procurement | 3 | 2023 | 311 | 0.520 |
Why?
|
Middle Aged | 36 | 2021 | 25028 | 0.520 |
Why?
|
Graft Rejection | 7 | 2022 | 1065 | 0.510 |
Why?
|
Zinc | 1 | 2015 | 91 | 0.500 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2014 | 19 | 0.500 |
Why?
|
Liver Failure, Acute | 1 | 2014 | 38 | 0.490 |
Why?
|
Male | 44 | 2021 | 40965 | 0.480 |
Why?
|
Hepatitis E | 1 | 2013 | 9 | 0.460 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2021 | 384 | 0.440 |
Why?
|
Kidney Transplantation | 3 | 2022 | 849 | 0.440 |
Why?
|
Pharmacy | 2 | 2022 | 7 | 0.440 |
Why?
|
Interferon-alpha | 3 | 2011 | 233 | 0.430 |
Why?
|
Acute Kidney Injury | 1 | 2016 | 295 | 0.430 |
Why?
|
Postoperative Complications | 6 | 2019 | 2207 | 0.430 |
Why?
|
Monitoring, Immunologic | 1 | 2012 | 17 | 0.430 |
Why?
|
Female | 41 | 2022 | 44532 | 0.420 |
Why?
|
Immunocompromised Host | 1 | 2013 | 140 | 0.420 |
Why?
|
Donor Selection | 1 | 2012 | 67 | 0.420 |
Why?
|
Practice Patterns, Physicians' | 2 | 2017 | 582 | 0.400 |
Why?
|
Hospitals | 2 | 2021 | 294 | 0.400 |
Why?
|
Hepatic Encephalopathy | 2 | 2023 | 40 | 0.400 |
Why?
|
Lung Transplantation | 2 | 2022 | 175 | 0.380 |
Why?
|
Biopsy | 5 | 2018 | 1163 | 0.370 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2018 | 40 | 0.360 |
Why?
|
Hepatitis B | 1 | 2010 | 74 | 0.350 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2012 | 425 | 0.350 |
Why?
|
United States | 11 | 2023 | 6672 | 0.320 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2014 | 763 | 0.320 |
Why?
|
Marfan Syndrome | 1 | 2007 | 28 | 0.310 |
Why?
|
Aged | 20 | 2022 | 18415 | 0.310 |
Why?
|
Hernia, Hiatal | 1 | 2007 | 30 | 0.300 |
Why?
|
Endoscopy, Digestive System | 1 | 2007 | 65 | 0.300 |
Why?
|
Polyethylene Glycols | 2 | 2010 | 363 | 0.300 |
Why?
|
Gastroenterology | 2 | 2021 | 134 | 0.300 |
Why?
|
Adult | 24 | 2021 | 25648 | 0.290 |
Why?
|
Living Donors | 2 | 2023 | 339 | 0.280 |
Why?
|
Liver Cirrhosis, Biliary | 2 | 2003 | 29 | 0.270 |
Why?
|
Hepatitis B, Chronic | 2 | 2016 | 32 | 0.270 |
Why?
|
Follow-Up Studies | 7 | 2021 | 3640 | 0.270 |
Why?
|
Liver | 4 | 2017 | 1230 | 0.270 |
Why?
|
Treatment Outcome | 15 | 2022 | 7993 | 0.260 |
Why?
|
Guanine | 2 | 2016 | 208 | 0.260 |
Why?
|
Cimicifuga | 1 | 2004 | 3 | 0.260 |
Why?
|
Mycophenolic Acid | 1 | 2005 | 87 | 0.250 |
Why?
|
Hepatitis | 3 | 2001 | 35 | 0.250 |
Why?
|
Cyclosporine | 2 | 2003 | 234 | 0.240 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2438 | 0.240 |
Why?
|
Retrospective Studies | 14 | 2017 | 8489 | 0.240 |
Why?
|
Cholestasis | 1 | 2004 | 47 | 0.240 |
Why?
|
Lactulose | 1 | 2023 | 19 | 0.240 |
Why?
|
Hypophosphatemia | 1 | 2003 | 8 | 0.230 |
Why?
|
Phytotherapy | 1 | 2004 | 133 | 0.230 |
Why?
|
Phosphorus | 1 | 2003 | 118 | 0.220 |
Why?
|
Nucleic Acids | 1 | 2023 | 30 | 0.220 |
Why?
|
Streptococcus | 1 | 2002 | 9 | 0.220 |
Why?
|
Plant Extracts | 1 | 2004 | 244 | 0.210 |
Why?
|
Streptococcal Infections | 1 | 2002 | 57 | 0.210 |
Why?
|
Risk Factors | 8 | 2022 | 5417 | 0.210 |
Why?
|
Genotype | 4 | 2013 | 1851 | 0.210 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 199 | 0.200 |
Why?
|
Incidence | 5 | 2022 | 1577 | 0.200 |
Why?
|
Transplant Recipients | 2 | 2021 | 122 | 0.200 |
Why?
|
Bacteremia | 1 | 2002 | 99 | 0.200 |
Why?
|
Fistula | 1 | 2021 | 42 | 0.200 |
Why?
|
Folic Acid Antagonists | 1 | 2000 | 19 | 0.190 |
Why?
|
Foreign-Body Migration | 1 | 2001 | 35 | 0.190 |
Why?
|
Hepatitis, Alcoholic | 1 | 2020 | 19 | 0.190 |
Why?
|
Gilbert Disease | 1 | 2000 | 1 | 0.190 |
Why?
|
RNA, Viral | 4 | 2017 | 327 | 0.190 |
Why?
|
Gastroenterologists | 1 | 2021 | 30 | 0.190 |
Why?
|
Job Satisfaction | 1 | 2021 | 73 | 0.190 |
Why?
|
Liver Diseases, Alcoholic | 1 | 2020 | 24 | 0.190 |
Why?
|
Methotrexate | 1 | 2000 | 249 | 0.180 |
Why?
|
Allografts | 2 | 2019 | 172 | 0.180 |
Why?
|
Internal Medicine | 2 | 2021 | 347 | 0.180 |
Why?
|
Internship and Residency | 2 | 2021 | 1004 | 0.180 |
Why?
|
Heart Failure | 3 | 2019 | 1204 | 0.180 |
Why?
|
Alanine Transaminase | 2 | 2013 | 73 | 0.180 |
Why?
|
Cholestasis, Intrahepatic | 1 | 1999 | 17 | 0.180 |
Why?
|
Neoplasms, Second Primary | 1 | 2002 | 252 | 0.180 |
Why?
|
Liver Function Tests | 2 | 2013 | 93 | 0.170 |
Why?
|
Drug Therapy, Combination | 6 | 2016 | 894 | 0.170 |
Why?
|
Isoenzymes | 1 | 2000 | 271 | 0.170 |
Why?
|
Autoimmune Diseases | 2 | 2001 | 241 | 0.170 |
Why?
|
Curriculum | 2 | 2021 | 539 | 0.170 |
Why?
|
Burnout, Professional | 1 | 2021 | 94 | 0.170 |
Why?
|
Multiple Organ Failure | 1 | 2019 | 53 | 0.170 |
Why?
|
Glucuronosyltransferase | 1 | 2000 | 184 | 0.170 |
Why?
|
Embolization, Therapeutic | 1 | 2021 | 238 | 0.160 |
Why?
|
Stents | 1 | 2001 | 377 | 0.160 |
Why?
|
Severity of Illness Index | 3 | 2017 | 1801 | 0.160 |
Why?
|
Time Factors | 5 | 2017 | 5210 | 0.160 |
Why?
|
Heart Defects, Congenital | 1 | 2021 | 351 | 0.160 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 346 | 0.160 |
Why?
|
Q Fever | 1 | 2017 | 8 | 0.150 |
Why?
|
Opiate Substitution Treatment | 1 | 2017 | 30 | 0.150 |
Why?
|
Sustained Virologic Response | 1 | 2017 | 8 | 0.150 |
Why?
|
Patient Selection | 2 | 2020 | 685 | 0.150 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2018 | 153 | 0.150 |
Why?
|
Fluorenes | 1 | 2016 | 8 | 0.150 |
Why?
|
Uridine Monophosphate | 1 | 2016 | 9 | 0.150 |
Why?
|
Fatal Outcome | 2 | 2014 | 293 | 0.150 |
Why?
|
Midodrine | 1 | 2016 | 5 | 0.150 |
Why?
|
Odds Ratio | 2 | 2016 | 678 | 0.150 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 859 | 0.140 |
Why?
|
Recurrence | 4 | 2016 | 1139 | 0.140 |
Why?
|
Paracentesis | 1 | 2016 | 8 | 0.140 |
Why?
|
Vasoconstrictor Agents | 1 | 2016 | 53 | 0.140 |
Why?
|
Students, Medical | 1 | 2021 | 384 | 0.140 |
Why?
|
Cardiac Surgical Procedures | 1 | 2001 | 462 | 0.140 |
Why?
|
Ascites | 1 | 2016 | 55 | 0.140 |
Why?
|
Non-alcoholic Fatty Liver Disease | 2 | 2017 | 212 | 0.140 |
Why?
|
Health Policy | 1 | 2017 | 180 | 0.140 |
Why?
|
Multidetector Computed Tomography | 1 | 2016 | 54 | 0.140 |
Why?
|
Young Adult | 6 | 2021 | 5976 | 0.140 |
Why?
|
Risk Assessment | 3 | 2017 | 2261 | 0.130 |
Why?
|
Benzimidazoles | 1 | 2016 | 140 | 0.130 |
Why?
|
Survival Rate | 2 | 2021 | 1863 | 0.130 |
Why?
|
Hospitalization | 3 | 2016 | 849 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 860 | 0.130 |
Why?
|
HIV Infections | 1 | 2004 | 772 | 0.130 |
Why?
|
Societies, Medical | 1 | 2019 | 572 | 0.130 |
Why?
|
Macrocyclic Compounds | 1 | 2014 | 7 | 0.130 |
Why?
|
Comorbidity | 2 | 2017 | 943 | 0.130 |
Why?
|
Carbamates | 1 | 2014 | 19 | 0.130 |
Why?
|
Gastrointestinal Diseases | 1 | 2016 | 146 | 0.130 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 136 | 0.130 |
Why?
|
Multivariate Analysis | 2 | 2015 | 999 | 0.130 |
Why?
|
Hepatitis B virus | 2 | 2015 | 43 | 0.130 |
Why?
|
Anilides | 1 | 2014 | 47 | 0.120 |
Why?
|
Early Diagnosis | 1 | 2015 | 131 | 0.120 |
Why?
|
Melanoma | 1 | 1999 | 459 | 0.120 |
Why?
|
Esophagitis | 1 | 2014 | 42 | 0.120 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 307 | 0.120 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 191 | 0.120 |
Why?
|
Prognosis | 3 | 2021 | 3679 | 0.120 |
Why?
|
Crohn Disease | 1 | 2000 | 730 | 0.120 |
Why?
|
Autoantibodies | 2 | 2014 | 267 | 0.120 |
Why?
|
Career Choice | 3 | 2021 | 139 | 0.120 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2014 | 94 | 0.120 |
Why?
|
Skin Neoplasms | 1 | 1999 | 546 | 0.120 |
Why?
|
Cohort Studies | 3 | 2016 | 2767 | 0.120 |
Why?
|
Colitis, Ulcerative | 1 | 2000 | 711 | 0.120 |
Why?
|
ABO Blood-Group System | 1 | 2014 | 62 | 0.120 |
Why?
|
Linear Models | 1 | 2015 | 421 | 0.120 |
Why?
|
Radiographic Image Enhancement | 1 | 2016 | 462 | 0.120 |
Why?
|
Hepatitis E virus | 1 | 2013 | 6 | 0.120 |
Why?
|
Roseolovirus Infections | 1 | 2013 | 7 | 0.110 |
Why?
|
Analgesics, Opioid | 1 | 2017 | 413 | 0.110 |
Why?
|
Herpesvirus 6, Human | 1 | 2013 | 19 | 0.110 |
Why?
|
Radiation Injuries | 1 | 2014 | 155 | 0.110 |
Why?
|
Ganciclovir | 1 | 2013 | 49 | 0.110 |
Why?
|
Aspartate Aminotransferases | 1 | 2013 | 73 | 0.110 |
Why?
|
Sirolimus | 1 | 2014 | 169 | 0.110 |
Why?
|
Disease Progression | 2 | 2015 | 1531 | 0.110 |
Why?
|
Isoantibodies | 1 | 2014 | 114 | 0.110 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2012 | 23 | 0.110 |
Why?
|
Aged, 80 and over | 4 | 2016 | 6509 | 0.110 |
Why?
|
Cooperative Behavior | 1 | 2014 | 174 | 0.110 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 466 | 0.110 |
Why?
|
Transplantation, Homologous | 3 | 2021 | 996 | 0.110 |
Why?
|
HLA Antigens | 1 | 2014 | 232 | 0.110 |
Why?
|
DNA, Viral | 1 | 2013 | 265 | 0.110 |
Why?
|
Hospitalists | 1 | 2014 | 131 | 0.110 |
Why?
|
Immunoassay | 1 | 2012 | 92 | 0.100 |
Why?
|
Case-Control Studies | 1 | 2016 | 1805 | 0.100 |
Why?
|
Immunity, Cellular | 1 | 2012 | 177 | 0.100 |
Why?
|
Fatty Liver | 1 | 2012 | 125 | 0.100 |
Why?
|
Recombinant Proteins | 3 | 2011 | 1014 | 0.100 |
Why?
|
Obesity | 1 | 2017 | 963 | 0.100 |
Why?
|
Consensus | 2 | 2022 | 335 | 0.100 |
Why?
|
Quality of Health Care | 1 | 2014 | 380 | 0.090 |
Why?
|
Mass Screening | 1 | 2015 | 618 | 0.090 |
Why?
|
Gastrointestinal Microbiome | 1 | 2016 | 455 | 0.090 |
Why?
|
Molecular Epidemiology | 1 | 2010 | 53 | 0.090 |
Why?
|
Biliary Fistula | 1 | 2009 | 11 | 0.090 |
Why?
|
Respiratory Tract Fistula | 1 | 2009 | 9 | 0.090 |
Why?
|
Neoplasms | 1 | 2004 | 2898 | 0.080 |
Why?
|
Toxocariasis | 1 | 2008 | 3 | 0.080 |
Why?
|
Global Health | 1 | 2010 | 193 | 0.080 |
Why?
|
Chronic Disease | 3 | 2016 | 971 | 0.080 |
Why?
|
Adolescent | 5 | 2019 | 8981 | 0.080 |
Why?
|
Gastroscopy | 1 | 2007 | 23 | 0.080 |
Why?
|
Waiting Lists | 2 | 2019 | 175 | 0.080 |
Why?
|
Aortic Rupture | 1 | 2007 | 55 | 0.070 |
Why?
|
Esophagoscopy | 1 | 2007 | 87 | 0.070 |
Why?
|
Anti-Inflammatory Agents | 2 | 2001 | 339 | 0.070 |
Why?
|
Biomarkers | 1 | 2013 | 1718 | 0.070 |
Why?
|
Hepatitis B e Antigens | 2 | 2016 | 8 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 746 | 0.070 |
Why?
|
Calcineurin Inhibitors | 2 | 2016 | 54 | 0.070 |
Why?
|
Amantadine | 1 | 2005 | 18 | 0.070 |
Why?
|
Cardiovascular Diseases | 1 | 2012 | 827 | 0.070 |
Why?
|
Retreatment | 1 | 2005 | 107 | 0.060 |
Why?
|
Prevalence | 2 | 2021 | 1239 | 0.060 |
Why?
|
Hot Flashes | 1 | 2004 | 11 | 0.060 |
Why?
|
Hemoglobins | 1 | 2005 | 179 | 0.060 |
Why?
|
Prednisone | 2 | 2003 | 258 | 0.060 |
Why?
|
Hospital Costs | 2 | 2016 | 105 | 0.060 |
Why?
|
Complementary Therapies | 1 | 2004 | 54 | 0.060 |
Why?
|
Biopsy, Needle | 1 | 2004 | 235 | 0.060 |
Why?
|
Logistic Models | 3 | 2012 | 1186 | 0.060 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2005 | 102 | 0.060 |
Why?
|
Clinical Competence | 2 | 2021 | 751 | 0.060 |
Why?
|
Bile Ducts | 1 | 2003 | 59 | 0.060 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2005 | 111 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2003 | 916 | 0.060 |
Why?
|
Blood Donors | 1 | 2023 | 26 | 0.060 |
Why?
|
Chickenpox Vaccine | 1 | 2002 | 7 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2004 | 268 | 0.060 |
Why?
|
Arthroplasty, Replacement | 1 | 2003 | 37 | 0.060 |
Why?
|
Chickenpox | 1 | 2002 | 39 | 0.050 |
Why?
|
Glucocorticoids | 2 | 2003 | 352 | 0.050 |
Why?
|
Advisory Committees | 1 | 2023 | 90 | 0.050 |
Why?
|
Pilot Projects | 1 | 2005 | 839 | 0.050 |
Why?
|
Polymerase Chain Reaction | 2 | 2017 | 927 | 0.050 |
Why?
|
Tacrolimus | 1 | 2003 | 373 | 0.050 |
Why?
|
Animals | 3 | 2023 | 26582 | 0.050 |
Why?
|
Antibodies, Viral | 1 | 2023 | 293 | 0.050 |
Why?
|
Recovery of Function | 1 | 2003 | 272 | 0.050 |
Why?
|
Yttrium Radioisotopes | 1 | 2021 | 46 | 0.050 |
Why?
|
Surveys and Questionnaires | 2 | 2021 | 2501 | 0.050 |
Why?
|
Salaries and Fringe Benefits | 1 | 2021 | 23 | 0.050 |
Why?
|
Training Support | 1 | 2021 | 23 | 0.050 |
Why?
|
Bilirubin | 1 | 2021 | 125 | 0.050 |
Why?
|
Hyperbilirubinemia | 1 | 2000 | 20 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2004 | 1753 | 0.050 |
Why?
|
Medicine | 1 | 2021 | 89 | 0.050 |
Why?
|
Cholangitis | 1 | 1999 | 19 | 0.040 |
Why?
|
Educational Measurement | 1 | 2021 | 225 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2021 | 207 | 0.040 |
Why?
|
Transition to Adult Care | 1 | 2019 | 22 | 0.040 |
Why?
|
Radiography, Thoracic | 1 | 2001 | 320 | 0.040 |
Why?
|
Child, Preschool | 2 | 2019 | 3612 | 0.040 |
Why?
|
Physician's Role | 1 | 2021 | 179 | 0.040 |
Why?
|
Cytomegalovirus Infections | 1 | 1999 | 144 | 0.040 |
Why?
|
Medicare | 1 | 2022 | 410 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2003 | 1673 | 0.040 |
Why?
|
Registries | 1 | 2022 | 702 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2021 | 379 | 0.040 |
Why?
|
Patient Compliance | 1 | 2019 | 227 | 0.040 |
Why?
|
Risk | 1 | 2019 | 674 | 0.040 |
Why?
|
Doxycycline | 1 | 2017 | 27 | 0.040 |
Why?
|
Methylprednisolone | 1 | 1997 | 66 | 0.040 |
Why?
|
Adiposity | 1 | 2017 | 70 | 0.040 |
Why?
|
Histocytochemistry | 1 | 2017 | 130 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 2601 | 0.040 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2016 | 4 | 0.040 |
Why?
|
Necrosis | 1 | 1997 | 204 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2017 | 98 | 0.040 |
Why?
|
Azathioprine | 1 | 1997 | 125 | 0.040 |
Why?
|
Sofosbuvir | 1 | 2016 | 18 | 0.040 |
Why?
|
Lung | 1 | 2023 | 1170 | 0.040 |
Why?
|
Alleles | 1 | 2000 | 1128 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2017 | 114 | 0.040 |
Why?
|
Drug Combinations | 1 | 2016 | 224 | 0.040 |
Why?
|
Cost Savings | 1 | 2016 | 66 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2015 | 24 | 0.030 |
Why?
|
Weight Loss | 1 | 2017 | 229 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2019 | 394 | 0.030 |
Why?
|
Quality Improvement | 1 | 2019 | 428 | 0.030 |
Why?
|
Health Status | 1 | 2017 | 360 | 0.030 |
Why?
|
2-Naphthylamine | 1 | 2014 | 1 | 0.030 |
Why?
|
Pediatrics | 1 | 2019 | 344 | 0.030 |
Why?
|
Cyclopropanes | 1 | 2014 | 25 | 0.030 |
Why?
|
Lactams, Macrocyclic | 1 | 2014 | 14 | 0.030 |
Why?
|
Bariatric Surgery | 1 | 2017 | 194 | 0.030 |
Why?
|
Ritonavir | 1 | 2014 | 12 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2016 | 144 | 0.030 |
Why?
|
Proline | 1 | 2014 | 57 | 0.030 |
Why?
|
Child | 2 | 2019 | 6927 | 0.030 |
Why?
|
Viral Nonstructural Proteins | 1 | 2014 | 37 | 0.030 |
Why?
|
Valine | 1 | 2014 | 69 | 0.030 |
Why?
|
Uracil | 1 | 2014 | 72 | 0.030 |
Why?
|
Observer Variation | 1 | 2016 | 602 | 0.030 |
Why?
|
Plasmapheresis | 1 | 2014 | 26 | 0.030 |
Why?
|
Transaminases | 1 | 2014 | 34 | 0.030 |
Why?
|
Complement C4b | 1 | 2014 | 35 | 0.030 |
Why?
|
Spouses | 1 | 2014 | 33 | 0.030 |
Why?
|
Body Mass Index | 1 | 2017 | 770 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2016 | 349 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 154 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 66 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 454 | 0.030 |
Why?
|
Heart Block | 1 | 2012 | 32 | 0.030 |
Why?
|
Length of Stay | 1 | 2016 | 702 | 0.030 |
Why?
|
Infant | 1 | 2019 | 3046 | 0.030 |
Why?
|
Fractures, Bone | 2 | 2005 | 131 | 0.030 |
Why?
|
Sulfonamides | 1 | 2014 | 300 | 0.030 |
Why?
|
Databases, Factual | 1 | 2016 | 814 | 0.030 |
Why?
|
Prospective Studies | 1 | 2021 | 4213 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2014 | 223 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2014 | 460 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 1991 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2012 | 109 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2012 | 187 | 0.020 |
Why?
|
Inpatients | 1 | 2014 | 297 | 0.020 |
Why?
|
Neuroblastoma | 1 | 2014 | 374 | 0.020 |
Why?
|
Drug Carriers | 1 | 2010 | 81 | 0.020 |
Why?
|
Treatment Failure | 1 | 2010 | 285 | 0.020 |
Why?
|
Obesity, Morbid | 1 | 2012 | 225 | 0.020 |
Why?
|
Mice | 1 | 2023 | 11352 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 11 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2012 | 376 | 0.020 |
Why?
|
Heart Arrest | 1 | 2012 | 265 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2014 | 724 | 0.020 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2009 | 62 | 0.020 |
Why?
|
Thoracotomy | 1 | 2009 | 58 | 0.020 |
Why?
|
Mutation | 1 | 2000 | 3968 | 0.020 |
Why?
|
Cats | 1 | 2008 | 303 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2014 | 1195 | 0.020 |
Why?
|
Cadaver | 1 | 2007 | 185 | 0.020 |
Why?
|
Tissue and Organ Harvesting | 1 | 2007 | 78 | 0.020 |
Why?
|
Hepatectomy | 1 | 2007 | 166 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 1169 | 0.020 |
Why?
|
Emergencies | 1 | 2005 | 113 | 0.020 |
Why?
|
Elective Surgical Procedures | 1 | 2005 | 116 | 0.020 |
Why?
|
Survival Analysis | 1 | 2007 | 1538 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 1141 | 0.010 |
Why?
|
Stroke | 1 | 2012 | 965 | 0.010 |
Why?
|
Osteonecrosis | 1 | 2003 | 21 | 0.010 |
Why?
|
Arthritis | 1 | 2003 | 46 | 0.010 |
Why?
|
Acyclovir | 1 | 2002 | 107 | 0.010 |
Why?
|
Postoperative Period | 1 | 2003 | 303 | 0.010 |
Why?
|
Hepatitis Antibodies | 1 | 2001 | 6 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 2003 | 263 | 0.010 |
Why?
|
Interferons | 1 | 2001 | 133 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 446 | 0.010 |
Why?
|